PMID- 15151480
OWN - NLM
STAT- MEDLINE
DCOM- 20041108
LR  - 20051116
IS  - 1477-9072 (Print)
IS  - 1477-9072 (Linking)
VI  - 2
IP  - 3
DP  - 2004 May
TI  - Clinical application of enoxaparin.
PG  - 321-37
AB  - Low-molecular-weight heparins have several important advantages over 
      unfractionated heparin (UFH). Due to a longer plasma half life together with high 
      bioavailability and a linear dose-response relationship, the drugs can be safely 
      and effectively administered in the hospital or ambulatory settings without the 
      need to monitor the anticoagulant effect. Enoxaparin (Lovenox), Aventis Pharma) 
      is a low-molecular-weight heparin which has been studied in a variety of clinical 
      situations. In general surgery the efficacy of enoxaparin to prevent venous 
      thromboembolism is similar to UFH but the tolerability is better. In patients 
      undergoing cancer, orthopedic or vascular surgery the efficacy of enoxaparin is 
      significantly higher with similar rates of bleeding complications. The database 
      for enoxaparin in nonsurgical patients is smaller compared with surgical groups. 
      There is evidence that the efficacy of enoxaparin may be superior to UFH in 
      patients with severe cardiac disease. Efficacy and safety of UFH and enoxaparin 
      are similar for the treatment of deep vein thrombosis. However, enoxaparin can be 
      safely administered by the patients at home which is not possible with UFH. In 
      patients with acute coronary syndromes, enoxaparin has been shown to reduce the 
      rate of deaths and serious cardiac events in comparison with UFH. Furthermore, 
      exonaparin treatment has been shown to be cost-effective, and therefore is the 
      therapy of choice in this setting. In addition, enoxaparin has been shown to be a 
      safe and effective alternative to the combination of UFH and phenprocoumone 
      therapy in patients undergoing electrical cardioversion for atrial fibrillation.
FAU - Hofmann, Thomas
AU  - Hofmann T
AD  - Universitatsklinikum Hamburg-Eppendorf, Herzzentrum, Medizinische Klinik III, 
      Martinistr. 52, 20246 Hamburg, Germany. thofmann@uke.uni-hamburg.de
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Fibrinolytic Agents)
SB  - IM
MH  - Anticoagulants/economics/*pharmacology/*therapeutic use
MH  - Cost-Benefit Analysis
MH  - Dose-Response Relationship, Drug
MH  - Enoxaparin/economics/*pharmacology/*therapeutic use
MH  - Fibrinolytic Agents/economics/pharmacology/therapeutic use
MH  - Humans
MH  - Myocardial Ischemia/drug therapy
MH  - Postoperative Complications/prevention & control
MH  - Pulmonary Embolism/prevention & control
MH  - Thrombocytopenia/chemically induced
MH  - Venous Thrombosis/prevention & control
RF  - 123
EDAT- 2004/05/21 05:00
MHDA- 2004/11/09 09:00
CRDT- 2004/05/21 05:00
PHST- 2004/05/21 05:00 [pubmed]
PHST- 2004/11/09 09:00 [medline]
PHST- 2004/05/21 05:00 [entrez]
AID - ERC020304 [pii]
AID - 10.1586/14779072.2.3.321 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2004 May;2(3):321-37. doi: 10.1586/14779072.2.3.321.